AVITA 10Q Quarterly Report for Q2 2025
Key points
- Consolidated revenue of $36.9 million for the six-months ended June 30, 2025
- Gross profit margin of 83% for the six-months ended June 30, 2025
- Net loss of $23.8 million for the six-months ended June 30, 2025
Full summary
AVITA Medical Inc. released its Q2 2025 quarterly report, highlighting the company's financial performance for the three-month and six-month periods ended June 30, 2025. The company reported consolidated revenue of $18.4 million and $36.9 million for the three-month and six-month periods, respectively, representing a year-over-year increase of 21% and 40%. Gross profit margin was 81% and 83% for the three-month and six-month periods, respectively. The company incurred a net loss of $9.9 million and $23.8 million for the three-month and six-month periods, respectively, primarily due to increased operating expenses related to sales and marketing, general and administrative, and research and development activities. AVITA's cash and cash equivalents balance stood at $12.2 million as of June 30, 2025, with $3.5 million in marketable securities. The company's financial statements included a going concern disclosure, indicating that certain conditions may impact its ability to continue as a going concern.
Summary generated by a large language model. Please interpret with care.